VCP-Eribulin

• Description:

  VCP-Eribulin consists the ADCs linker (VCP) and Eribulin[1]. Eribulin is a mechanistically unique microtubule inhibitor for cancer[2]. VCP-Eribulin is an Eribulin-based agent for antibody conjugates[1].

• UNSPSC:

  12352203

• Target:

  Drug-Linker Conjugates for ADC

• Type:

  ADC Related

• Related Pathways:

  Antibody-drug Conjugate/ADC Related

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/vcp-eribulin.html

• Solubility:

  10 mM in DMSO

• Smiles:

  C=C1C[C@@]2([H])O[C@@]1([H])CC[C@]3([H])O[C@](C([C@H](C)C3)=C)([H])C[C@@]4([H])[C@]([C@@H](OC)[C@@H](C[C@H](O)CNC(OCC5=CC=C(NC([C@H](CCCNC(N)=O)NC([C@H](C(C)C)N)=O)=O)C=C5)=O)O4)([H])CC(C[C@]6([H])O[C@]7([H])[C@]8([H])O[C@@]9(O[C@@]%10([H])[C@@](O[C@]8([H])[C@@]%10([H])O[C@@]7([H])CC6)([H])C9)CC2)=O

• Molecular Formula:

  C59H86N6O16

• Molecular Weight:

  1135.34

• References & Citations:

  [1]Earl F Albone, et al. Eribulin-based antibody-drug conjugates and methods of use. US20170252458A1.|[2]Towle MJ, et al. Eribulin induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions. Cancer Res. 2011 Jan 15;71 (2) :496-505.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  ADC Related

• Clinical Information:

  No Development Reported

• Isoform:

  Traditional Cytotoxic Agents

• CAS Number:

  [2130869-17-7]